Jane Street Group LLC Has $70,000 Stock Holdings in Cue Biopharma, Inc. (NASDAQ:CUE)

Jane Street Group LLC boosted its holdings in shares of Cue Biopharma, Inc. (NASDAQ:CUE) by 145.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,767 shares of the company’s stock after acquiring an additional 37,832 shares during the quarter. Jane Street Group LLC owned 0.10% of Cue Biopharma worth $70,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Stifel Financial Corp lifted its stake in shares of Cue Biopharma by 8.8% in the fourth quarter. Stifel Financial Corp now owns 211,361 shares of the company’s stock worth $230,000 after acquiring an additional 17,139 shares during the period. XTX Topco Ltd raised its holdings in Cue Biopharma by 69.8% during the 4th quarter. XTX Topco Ltd now owns 46,973 shares of the company’s stock worth $51,000 after purchasing an additional 19,308 shares during the last quarter. LPL Financial LLC lifted its position in shares of Cue Biopharma by 139.5% in the 4th quarter. LPL Financial LLC now owns 42,929 shares of the company’s stock worth $47,000 after purchasing an additional 25,004 shares during the period. Texas Capital Bank Wealth Management Services Inc acquired a new position in shares of Cue Biopharma in the 4th quarter worth approximately $36,000. Finally, HighTower Advisors LLC boosted its stake in shares of Cue Biopharma by 54.0% in the 4th quarter. HighTower Advisors LLC now owns 128,284 shares of the company’s stock valued at $140,000 after purchasing an additional 45,000 shares during the last quarter. 35.04% of the stock is currently owned by institutional investors and hedge funds.

Cue Biopharma Trading Up 1.7%

CUE opened at $0.64 on Monday. Cue Biopharma, Inc. has a twelve month low of $0.45 and a twelve month high of $1.99. The company has a fifty day moving average of $0.72 and a 200-day moving average of $1.02. The stock has a market cap of $48.30 million, a PE ratio of -0.71 and a beta of 1.41. The company has a quick ratio of 2.22, a current ratio of 2.22 and a debt-to-equity ratio of 0.05.

Cue Biopharma (NASDAQ:CUE) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The business had revenue of $0.42 million for the quarter, compared to analyst estimates of $0.90 million. Cue Biopharma had a negative return on equity of 156.38% and a negative net margin of 468.02%. On average, sell-side analysts predict that Cue Biopharma, Inc. will post -0.76 EPS for the current year.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.